Cognitive deficits in Parkinsonâ€⁵\disease

Journal of Neurology 244, 2-8

DOI: 10.1007/pl00007725

Citation Report

#	Article	IF	CITATIONS
1	Neuropsychological Impairment in Parkinson's Disease With and Without Depression. Archives of Neurology, 1995, 52, 1164-1169.	4.9	158
2	Parkinson's Disease Affects Automatic and Spares Intentional Verbal Learning a Stochastic Approach to Explicit Learning Processes. Cortex, 1995, 31, 597-617.	1.1	16
3	Visual selective attention deficits in patients with Parkinson's disease: A quantitative model-based approach Neuropsychology, 1996, 10, 197-218.	1.0	47
4	Memory for spatial location is affected in Parkinson's disease. Neuropsychologia, 1996, 34, 77-85.	0.7	60
5	Functional Effects of Striatal Dysfunction in Parkinson Disease. Archives of Neurology, 1997, 54, 145-150.	4.9	103
6	Performance of Parkinson's Disease Patients on the Visual Search and Attention Test: Impairment in Single-Feature but not Dual-Feature Visual Search. Archives of Clinical Neuropsychology, 1997, 12, 621-634.	0.3	15
7	THE ROLE OF THE THALAMUS AND BASAL GANGLIA IN HUMAN COGNITION. Journal of Neurolinguistics, 1997, 10, 255-265.	0.5	17
8	An examination of the nature of attentional deficits in patients with Parkinson's disease: Evidence from a spatial orienting task. Journal of the International Neuropsychological Society, 1997, 3, 337-347.	1.2	63
9	A study of visual hallucinations in patients with Parkinson's disease. Journal of Neurology, 1997, 244, 371-377.	1.8	61
10	Memory and depression in Parkinson's disease. European Journal of Neurology, 1998, 5, 291-295.	1.7	17
11	Mental dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 1998, 4, 107-112.	1.1	37
12	Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology, 1998, 50, 1289-1293.	1.5	81
13	Prospective comparative study of the evolution of probable Alzheimer's disease and Parkinson's disease dementia. Journal of the International Neuropsychological Society, 1998, 4, 279-284.	1.2	24
14	Lexical entries and rules of language: A multidisciplinary study of German inflection. Behavioral and Brain Sciences, 1999, 22, 991-1013.	0.4	552
15	Inflectional morphology in a family with inherited specific language impairment. Applied Psycholinguistics, 1999, 20, 51-117.	0.8	143
16	Wisconsin Card Sorting Test Variables in Relation to Motor Symptoms in Parkinson's Disease. Perceptual and Motor Skills, 1999, 89, 824-830.	0.6	14
17	Range of neuropsychiatric disturbances in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 492-496.	0.9	484
18	Cognitive outcome after unilateral pallidal stimulation in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 297-304.	0.9	94

#	Article	IF	Citations
19	Verbal Working Memory Deficit in Parkinson's Disease Subjects. European Neurology, 1999, 42, 90-94.	0.6	19
20	Bilateral subthalamic nucleus stimulation improves frontal cortex function in Parkinson's disease. Brain, 1999, 122, 2365-2373.	3.7	92
21	A hard wired model of coupled frontal working memories for various tasks. Information Sciences, 1999, 113, 221-243.	4.0	18
22	Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys. Psychopharmacology, 1999, 147, 104-107.	1.5	29
23	Early diagnosis of dementia: neuropsychology. Journal of Neurology, 1999, 246, 6-15.	1.8	288
24	Neuropsychiatric aspects of parkinson's disease. Current Psychiatry Reports, 1999, 1, 61-68.	2.1	57
25	Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Annals of Neurology, 1999, 46, 62-69.	2.8	187
26	Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: A consecutive series of 62 patients. Annals of Neurology, 1999, 46, 217-223.	2.8	414
27	Event-related potentials reveal memory deficits in Parkinson's disease. Cognitive Brain Research, 1999, 8, 165-172.	3.3	21
28	Consistency of handwriting movements in dementia of the Alzheimer's type: A comparison with Huntington's and Parkinson's diseases. Journal of the International Neuropsychological Society, 1999, 5, 20-25.	1.2	62
29	Visual event-related potential changes at two different tasks in nondemented Parkinson's disease. Journal of the Neurological Sciences, 1999, 164, 139-147.	0.3	21
30	The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. Journal of the Neurological Sciences, 1999, 166, 141-151.	0.3	148
31	Rule-Based Learning Impairment in Rats with Lesions to the Dorsal Striatum. Neurobiology of Learning and Memory, 1999, 72, 47-61.	1.0	25
32	Spoken Language Production in Huntington's and Parkinson's Diseases. Journal of Speech, Language, and Hearing Research, 2000, 43, 1350-1366.	0.7	102
33	Attentional Bias toward Low-Intensity Stimuli: An Explanation for the Intensity Dissociation between Reaction Time and Temporal Order Judgment?. Consciousness and Cognition, 2000, 9, 435-456.	0.8	34
34	Neuropsychologic assessment of patients for movement disorder surgery. Movement Disorders, 2000, 15, 771-783.	2.2	91
35	Cognitive processes involved in delayed non-matching-to-sample performance in Parkinson's disease. European Journal of Neurology, 2000, 7, 473-483.	1.7	21
36	Understanding memory for faces in Parkinson's disease: the role of configural processing. Neuropsychologia, 2000, 38, 837-847.	0.7	31

#	Article	IF	CITATIONS
37	Visual feedback has differential effects on reaching movements in Parkinson's and Alzheimer's disease. Brain Research, 2000, 876, 112-123.	1.1	117
38	Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration, and Parkinson's disease. Journal of Neurology, 2000, 247, 356-363.	1.8	33
39	Intracerebral Transplants and Memory Dysfunction: Circuitry Repair or Functional Level Setting?. Neural Plasticity, 2000, 7, 93-108.	1.0	3
40	Neuropsychological changes between "off―and "on―STN or GPi stimulation in Parkinson's disease. Neurology, 2000, 55, 411-418.	1.5	313
41	Basal Ganglia Output and Cognition: Evidence from Anatomical, Behavioral, and Clinical Studies. Brain and Cognition, 2000, 42, 183-200.	0.8	589
42	Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Research Reviews, 2000, 31, 236-250.	9.1	1,677
43	Neuropsychiatric Aspects of Parkinson's Disease. Psychosomatics, 2000, 41, 15-23.	2.5	94
44	Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain, 2000, 123, 2091-2108.	3.7	488
45	The neural correlates of `deaf-hearing' in man: Conscious sensory awareness enabled by attentional modulation. Brain, 2000, 123, 532-545.	3.7	66
46	Involvement of Non-Dopaminergic Pathways in Parkinson???s Disease. CNS Drugs, 2000, 13, 351-364.	2.7	19
47	Anxiety disorders in Parkinson's disease. International Review of Psychiatry, 2000, 12, 307-318.	1.4	40
48	Novel drug development for amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2000, 180, 21-28.	0.3	26
49	Impaired Perception of Vocal Emotions in Parkinson's Disease: Influence of Speech Time Processing and Executive Functioning. Brain and Cognition, 2001, 45, 277-314.	0.8	115
50	Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Research Bulletin, 2001, 55, 101-106.	1.4	92
51	Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neuroscience Letters, 2001, 311, 81-84.	1.0	157
52	Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behavioural Brain Research, 2001, 124, 9-18.	1.2	109
53	Recognition memory in normal aging and Parkinson's disease: behavioral and electrophysiologic measures. Cognitive Brain Research, 2001, 11, 23-32.	3.3	23
54	Functional brain networks in Parkinson's disease. Parkinsonism and Related Disorders, 2001, 8, 91-94.	1.1	33

#	Article	IF	CITATIONS
55	Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiologie Clinique, 2001, 31, 321-340.	1.0	58
56	Audio and vision-based evaluation of parkinson~s disease from discourse video., 2001,,.		2
57	Concurrent Validity of the Test of Nonverbal Intelligence in Parkinson's Disease Patients. Journal of Psychology: Interdisciplinary and Applied, 2001, 135, 205-212.	0.9	12
58	Tactile Discrimination Task Not Disturbed by Thalamic Stimulation. Stereotactic and Functional Neurosurgery, 2001, 76, 19-28.	0.8	6
59	Mechanisms of cognitive set flexibility in Parkinson's disease. Brain, 2001, 124, 2503-2512.	3.7	344
60	Motor perseveration is an early sign of Parkinson's disease. Neurology, 2001, 57, 2111-2113.	1.5	46
61	L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. International Journal of Neuropsychopharmacology, 2001, 4, 361-70.	1.0	48
62	Deep brain stimulation in neuropsychiatric disorders. Current Psychiatry Reports, 2001, 3, 366-372.	2.1	13
63	Motor imagery in Parkinson's disease: A PET study. Movement Disorders, 2001, 16, 849-857.	2.2	54
64	Functional networks in motor sequence learning: Abnormal topographies in Parkinson's disease. Human Brain Mapping, 2001, 12, 42-60.	1.9	134
65	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. International Journal of Geriatric Psychiatry, 2001, 16, 528-536.	1.3	321
66	Intrinsic and extrinsic psychosis in Parkinson's disease. Journal of Neurology, 2001, 248, 22-27.	1.8	72
67	Basal ganglia dysfunction, working memory, and sentence comprehension in patients with Parkinson's disease. Neuropsychologia, 2001, 39, 962-971.	0.7	47
68	Automatic orienting of visuospatial attention in Parkinson's disease. Neuropsychologia, 2001, 39, 1240-1249.	0.7	75
69	Executive dysfunction in subcortical ischaemic vascular disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 217-220.	0.9	227
70	Relationships Among the Metabolic Patterns That Correlate With Mnemonic, Visuospatial, and Mood Symptoms in Parkinson's Disease. American Journal of Psychiatry, 2002, 159, 746-754.	4.0	147
71	Manipulation of working memory information is impaired in Parkinson's disease and related to working memory capacity Neuropsychology, 2002, 16, 577-590.	1.0	46
72	Dopamine Modulates the Response of the Human Amygdala: A Study in Parkinson's Disease. Journal of Neuroscience, 2002, 22, 9099-9103.	1.7	261

#	Article	IF	Citations
73	Procedural Skill Learning in Obstructive Sleep Apnea Syndrome. Sleep, 2002, 25, 398-408.	0.6	56
74	Dissecting the Brain's Internal Clock: How Frontal–Striatal Circuitry Keeps Time and Shifts Attention. Brain and Cognition, 2002, 48, 195-211.	0.8	293
75	Higher brain function disturbance in Parkinson's disease patients: an evaluation based on electrophysiological investigation. International Congress Series, 2002, 1247, 521-537.	0.2	0
76	l-dopa effects on preprogramming and control activity in a skilled motor act in Parkinson's disease. Clinical Neurophysiology, 2002, 113 , 243 - 253 .	0.7	14
77	Cognition and the inhibitory control of saccades in schizophrenia and Parkinson's disease. Progress in Brain Research, 2002, 140, 449-466.	0.9	44
78	The Adaptive Digit Ordering Test Clinical application, reliability, and validity of a verbal working memory test. Archives of Clinical Neuropsychology, 2002, 17, 547-565.	0.3	66
79	Parkinson's disease: the thalamic components of the limbic loop are severely impaired by α-synuclein immunopositive inclusion body pathology. Neurobiology of Aging, 2002, 23, 245-254.	1.5	117
80	The microvascular frontal-subcortical syndrome of aging. Neurobiology of Aging, 2002, 23, 421-431.	1.5	217
81	Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Research Bulletin, 2002, 58, 41-47.	1.4	144
82	Pathophysiological brain mapping in Parkinson's disease. International Congress Series, 2002, 1232, 571-577.	0.2	0
83	ERPs elicited by go and category deviant no-go stimuli in Parkinson's disease. International Congress Series, 2002, 1232, 567-570.	0.2	0
84	The Neuropsychological Assessment of Dementia. CNS Spectrums, 2002, 7, 371-375.	0.7	0
85	Differential neurobehavioral deficits induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in rats. European Journal of Pharmacology, 2002, 443, 105-111.	1.7	29
86	Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. Pharmacology Biochemistry and Behavior, 2002, 73, 843-850.	1.3	25
87	Immunohistochemical localization of GDNF in the human hippocampal formation from prenatal life to adulthood. Brain Research, 2002, 928, 138-146.	1.1	12
88	Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. Movement Disorders, 2002, 17, 1077-1083.	2.2	83
89	Psychophysiological approach in Parkinson's disease: L-dopa effects on preprogramming and control activity. Neurological Sciences, 2002, 23, s73-s74.	0.9	1
90	Insufficient processing resources in Parkinson's disease: evaluation using multimodal event-related potentials paradigm. Brain Topography, 2002, 14, 299-311.	0.8	17

#	Article	IF	CITATIONS
91	The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cellular and Molecular Neurobiology, 2002, 22, 227-237.	1.7	103
92	Burst activity of spiny projection neurons in the striatum encodes superimposed muscle tetani in cataleptic rats. Experimental Brain Research, 2003, 152, 519-522.	0.7	10
93	Cognitve estimation: comparison of two tests in nondemented parkinsonian patients. Neurological Sciences, 2003, 24, 153-154.	0.9	12
94	Activation of basal ganglia loops in idiopathic Parkinson?s disease: a PET study. Journal of Neural Transmission, 2003, 110, 1289-1301.	1.4	109
95	Verbs with alternating transitivity in Parkinson's disease: Evidence from production and comprehension tasks. Brain and Language, 2003, 87, 63-64.	0.8	4
96	Early stage Parkinson's disease patients and normal volunteers: Comparative mechanisms of sequence learning. Human Brain Mapping, 2003, 20, 246-258.	1.9	40
97	Deficit of verb generation in nondemented patients with Parkinson's disease. Movement Disorders, 2003, 18, 150-156.	2.2	128
98	Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Movement Disorders, 2003, 18, 524-530.	2.2	231
99	Depressed mood and executive dysfunction in early Parkinson's disease. Acta Neurologica Scandinavica, 2003, 107, 341-348.	1.0	58
100	Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients. Journal of the Neurological Sciences, 2003, 213, 61-65.	0.3	13
101	Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 2003, 24, 197-211.	1.5	8,567
102	Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system. Neurobiology of Learning and Memory, 2003, 79, 236-242.	1.0	87
103	Deficits on Corsi's block-tapping task in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2003, 10, 107-111.	1.1	23
104	Minimal Hepatic Encephalopathy and Extrapyramidal Signs in Patients With Cirrhosis. American Journal of Gastroenterology, 2003, 98, 1599-1604.	0.2	40
105	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1215-1220.	0.9	199
106	Frontal-striatal circuit functions: Context, sequence, and consequence. Journal of the International Neuropsychological Society, 2003, 9, 103-128.	1.2	166
107	Regional Cerebral Blood Flow and Episodic Memory in Parkinson's Disease: A Single Photon Emission Tomography Study. European Neurology, 2003, 49, 238-242.	0.6	5
108	Predictors of cognitive impairment in advanced Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 793-796.	0.9	48

#	Article	IF	Citations
109	High-level language difficulties in Parkinson's disease. Clinical Linguistics and Phonetics, 2003, 17, 63-80.	0.5	90
110	Event based and time based prospective memory in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 704-709.	0.9	75
111	Dopamine and cognitive function. Current Opinion in Neurology, 2003, 16, S17-S22.	1.8	63
112	A Review of the Cognitive and Behavioral Sequelae of Parkinson's Disease: Relationship to Frontostriatal Circuitry. Cognitive and Behavioral Neurology, 2003, 16, 193-210.	0.5	365
113	Neuropsychology for Movement Disorders Neurosurgery. Canadian Journal of Neurological Sciences, 2003, 30, S83-S93.	0.3	7
114	Pharmacological evidence of the role of dorsal striatum in spatial memory consolidation in mice Behavioral Neuroscience, 2003, 117, 685-694.	0.6	15
115	Category learning deficits in Parkinson's disease Neuropsychology, 2003, 17, 115-124.	1.0	116
116	Visuospatial dysfunction in the neurodegenerative diseases. Frontiers in Bioscience - Landmark, 2003, 8, e428-436.	3.0	37
117	Decision-Making Impairments in Patients with Parkinson's Disease. Behavioural Neurology, 2004, 15, 77-85.	1.1	198
118	Behavioural disorders induced by external globus pallidus dysfunction in primates II. Anatomical study. Brain, 2004, 127, 2055-2070.	3.7	171
119	The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPalGN study. Brain, 2004, 127, 550-560.	3.7	605
120	Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology, 2004, 63, 293-300.	1.5	215
121	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 137-145.	1.2	180
122	Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity. European Journal of Neuroscience, 2004, 19, 426-436.	1.2	25
123	Deficits in decoding emotional facial expressions in Parkinson's disease. Neuropsychologia, 2004, 42, 239-250.	0.7	170
124	The primate working memory networks. Cognitive, Affective and Behavioral Neuroscience, 2004, 4, 444-465.	1.0	160
125	Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research, 2004, 318, 121-134.	1.5	2,272
126	Cognitive dysfunction and dementia in Parkinson?s disease. Journal of Neural Transmission, 2004, 111, 1303-1315.	1.4	238

#	Article	IF	CITATIONS
127	Cognitive and behavioral dysfunction in Parkinson?s disease: neurochemical and clinicopathological contributions. Journal of Neural Transmission, 2004, 111, 1287-1301.	1.4	119
128	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 2004, 19, 371-377.	1.3	119
129	Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. International Journal of Geriatric Psychiatry, 2004, 19, 1-8.	1.3	223
130	The Neural Substrates of Reward Processing in Humans: The Modern Role of fMRI. Neuroscientist, 2004, 10, 260-268.	2.6	390
131	Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys. Behavioural Brain Research, 2004, 152, 259-262.	1.2	24
132	Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience, 2004, 123, 349-359.	1.1	241
133	Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats?. Neurobiology of Learning and Memory, 2004, 82, 150-158.	1.0	36
134	PET/SPECT characterization of cognitive deficits in Parkinson's disease. International Congress Series, 2004, 1264, 26-32.	0.2	0
135	Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1467-1469.	0.9	206
136	Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. NeuroImage, 2004, 22, 553-561.	2.1	80
137	PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. NeuroImage, 2004, 23, 1-16.	2.1	90
138	Psychiatric aspects of Parkinson's disease. Current Opinion in Psychiatry, 2005, 18, 335-341.	3.1	12
139	Maintenance of Response Readiness in Patients With Parkinson's Disease: Evidence From a Simple Reaction Time Task Neuropsychology, 2005, 19, 54-65.	1.0	9
140	Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: Histological, neurochemical, motor and memory alterations. Journal of Neuroscience Methods, 2005, 148, 78-87.	1.3	181
141	Dual tasking, gait rhythmicity, and Parkinson's disease: Which aspects of gait are attention demanding?. European Journal of Neuroscience, 2005, 22, 1248-1256.	1.2	659
142	Neural correlates of lexicon and grammar: Evidence from the production, reading, and judgment of inflection in aphasia. Brain and Language, 2005, 93, 185-238.	0.8	174
143	Impaired intentional content learning but spared incidental retention of contextual information in non-demented patients with Parkinson's disease. Neuropsychologia, 2005, 43, 675-681.	0.7	29
144	Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor. Pharmacology Biochemistry and Behavior, 2005, 81, 701-708.	1.3	51

#	Article	IF	Citations
145	Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. Journal of Neurology, 2005, 252, 1345-1352.	1.8	129
146	Progression of Cognitive Impairments Associated With Cerebrovascular Disease., 2005, , 145-156.		1
147	An Effect of Dopamine Depletion on Decision-making: The Temporal Coupling of Deliberation and Execution. Journal of Cognitive Neuroscience, 2005, 17, 1886-1896.	1.1	37
148	Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology, 2005, 64, 1404-1410.	1.5	509
149	Planning and realisation of complex intentions in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1501-1505.	0.9	65
150	Lack of behavioural effects after acute tyrosine depletion in healthy volunteers. Journal of Psychopharmacology, 2005, 19, 5-11.	2.0	31
151	Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology, 2005, 64, 224-229.	1.5	280
152	Dimensions of Executive Function in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 140-144.	0.7	83
153	Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1204-1210.	0.9	78
154	fMRI experiments and computational models of the function of the prefrontal cortex and the basal ganglia: a review. , 0 , , .		0
155	Psychiatric Complications in Parkinson Disease. American Journal of Geriatric Psychiatry, 2005, 13, 844-851.	0.6	105
156	Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Experimental Neurology, 2005, 192, 134-141.	2.0	48
157	Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease?. Parkinsonism and Related Disorders, 2005, 11, 311-315.	1.1	20
158	The feasibility of using cognitive behaviour therapy for depression associated with Parkinson's disease: A literature review. Parkinsonism and Related Disorders, 2005, 11, 269-276.	1.1	37
159	Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiology of Aging, 2005, 26, 891-898.	1.5	112
160	On the neural basis of focused and divided attention. Cognitive Brain Research, 2005, 25, 760-776.	3.3	114
161	Parkinson's disease: premotor clinico-pathological correlations. , 2006, , 309-319.		154
162	Metamemory Monitoring and Parkinson's Disease. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 618-630.	0.8	30

#	Article	IF	CITATIONS
163	Psychiatric Aspects of Parkinson's Disease. , 2006, , 163-176.		0
165	Event-related desynchronization/synchronization during an auditory–verbal working memory task in mild Parkinson's disease. Clinical Neurophysiology, 2006, 117, 1737-1745.	0.7	19
166	Resting state oscillatory brain dynamics in Parkinson's disease: An MEG study. Clinical Neurophysiology, 2006, 117, 2521-2531.	0.7	173
167	Postural Control, Gait, and Dopamine Functions in Parkinsonian Movement Disorders. Clinics in Geriatric Medicine, 2006, 22, 797-812.	1.0	56
168	Cognitive, Affective, and Psychiatric Features of Parkinson's Disease. Clinics in Geriatric Medicine, 2006, 22, 773-796.	1.0	30
169	Virtual Action Planning in Parkinson's Disease: AControl Study. Cyberpsychology, Behavior and Social Networking, 2006, 9, 342-347.	2.2	77
170	Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function. Biological Psychiatry, 2006, 59, 898-907.	0.7	258
171	Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: A review. Journal of the Neurological Sciences, 2006, 248, 104-114.	0.3	30
172	Putamen FDOPA uptake and its relationship tot cognitive functioning in PD. Journal of the Neurological Sciences, 2006, 248, 68-71.	0.3	21
173	An Examination of Executive Dysfunction Associated with Frontostriatal Circuitry in Parkinson's Disease. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1127-1144.	0.8	154
174	The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Experimental Neurology, 2006, 202, 391-403.	2.0	99
175	Relationship between event-related potentials and frontal-subcortical dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 453-458.	1.1	19
176	Neuropharmacological Treatment of Mental Dysfunction in Parkinson's Disease. Behavioural Neurology, 2006, 17, 43-51.	1.1	13
177	Cholinesterase inhibitors for Parkinson's disease dementia. The Cochrane Library, 2006, , CD004747.	1.5	63
178	The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: A meta-analysis. Journal of the International Neuropsychological Society, 2006, 12, 368-82.	1.2	56
179	Clinical management of Parkinson's disease dementia: pitfalls and progress. Advances in Psychiatric Treatment, 2006, 12, 121-129.	0.6	7
180	Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. European Journal of Neuroscience, 2006, 24, 2098-2104.	1.2	28
181	Parkinson's disease with dementia and dementia with Lewy body disease: two syndromes, the same disease?. Psychogeriatrics, 2006, 6, S30-S34.	0.6	2

#	ARTICLE	IF	CITATIONS
182	The Frequency of Reversible Parkinsonism and Cognitive Decline Associated with Valproate Treatment: A Study of 364 Patients with Different Types of Epilepsy. Epilepsia, 2006, 47, 2183-2185.	2.6	72
183	The molecular genetics of cognition: dopamine, COMT and BDNF. Genes, Brain and Behavior, 2006, 5, 311-328.	1.1	275
184	Dopaminergic modulation of cognitive function-implications for I-DOPA treatment in Parkinson's disease. Neuroscience and Biobehavioral Reviews, 2006, 30, 1-23.	2.9	778
185	The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. Journal of Neurology, 2006, 253, 171-175.	1.8	47
186	Impulse control disorders in parkinson's disease. Current Neurology and Neuroscience Reports, 2006, 6, 302-306.	2.0	66
187	Action fluency in Parkinson's disease: A follow-up study. Movement Disorders, 2006, 21, 467-472.	2.2	50
188	Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Movement Disorders, 2006, 21, 148-158.	2.2	312
189	Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease. Movement Disorders, 2006, 21, 337-342.	2.2	103
190	The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Movement Disorders, 2006, 21, 500-509.	2.2	41
191	Deep brain stimulation: Neuropsychological and neuropsychiatric issues. Movement Disorders, 2006, 21, S305-S327.	2.2	357
192	Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia. Movement Disorders, 2006, 21, 1343-1349.	2.2	541
193	Neuropsychological profile of DYT1 dystonia. Movement Disorders, 2006, 21, 2073-2077.	2.2	45
194	Functional role of the basal ganglia in the planning and execution of actions. Annals of Neurology, 2006, 59, 257-264.	2.8	307
195	Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain, 2006, 130, 233-244.	3.7	214
196	Recognition and management of neuropsychiatric complications in Parkinson's disease. Cmaj, 2006, 175, 1545-1552.	0.9	56
197	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 254-259.	0.9	235
198	Performance Monitoring and Error Processing During a Lexical Decision Task in Patients With Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 46-54.	1.2	45
199	A Common Cognitive Profile in Elderly Fallers and in Patients with Parkinson's Disease: The Prominence of Impaired Executive Function and Attention. Experimental Aging Research, 2006, 32, 411-429.	0.6	159

#	Article	IF	Citations
200	Parkinsons Disease: Genetics and Beyond. Current Neuropharmacology, 2007, 5, 99-113.	1.4	28
201	Auditory and Visual Recognition Memory in Normal Aging and Parkinson's Disease: An Event-Related Potential Study., 2007,,.		0
202	Heterogeneity of Cognitive Dysfunction in Parkinson's Disease: A Cohort Study. European Neurology, 2007, 58, 34-40.	0.6	21
203	Functional Ability Correlates with Cognitive Impairment in Parkinson's Disease and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2007, 24, 327-334.	0.7	38
205	Recognition memory for unfamiliar faces in Parkinson's disease: Behavioral and electrophysiologic measures. Parkinsonism and Related Disorders, 2007, 13, 157-164.	1.1	18
206	Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease. Neurobiology of Learning and Memory, 2007, 87, 451-463.	1.0	21
207	Cognitive function assessment in idiopathic Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2007, 65, 942-946.	0.3	20
208	Fatigue in Parkinson's disease: A review. Movement Disorders, 2007, 22, 297-308.	2.2	294
209	Cognitive dysfunction and dementia in Parkinson disease. Movement Disorders, 2007, 22, S358-S366.	2.2	188
210	Dysautonomia and cognitive dysfunction in Parkinson's disease. Movement Disorders, 2007, 22, S374-S378.	2.2	50
211	Impact of 6-hydroxydopamine lesions and cocaine exposure on $\hat{A}\mu$ -opioid receptor expression and regulation of cholinergic transmission in the limbic-prefrontal territory of the rat dorsal striatum. European Journal of Neuroscience, 2007, 25, 1546-1556.	1.2	7
212	Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. European Journal of Neuroscience, 2007, 25, 3132-3136.	1.2	64
213	Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: implication of new neurokinine 1â€sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission. Journal of Neurochemistry, 2007, 103, 2153-2163.	2.1	15
214	Impaired attentional modulation of auditory evoked potentials in N-methyl-d-aspartate NR1 hypomorphic mice. Genes, Brain and Behavior, 2007, 6, 558-568.	1.1	17
215	Functional Imaging of Working Memory in Parkinson's Disease: Compensations and Deficits. Journal of Neuroimaging, 2007, 17, 277-285.	1.0	17
216	Characterizing rule-based category learning deficits in patients with Parkinson's disease. Neuropsychologia, 2007, 45, 305-320.	0.7	36
217	Impaired self-initiated task preparation during task switching in Parkinson's disease. Neuropsychologia, 2007, 45, 273-281.	0.7	34
218	Recognition, recollection, familiarity and executive function in medicated patients with moderate Parkinson's disease. Journal of Neuropsychology, 2007, 1, 131-147.	0.6	28

#	Article	IF	Citations
219	Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology, 2007, 194, 517-525.	1.5	68
220	Epidemiology of Parkinson's disease. Journal of Neurology, 2008, 255, 18-32.	1.8	314
221	The role of executive function and attention in gait. Movement Disorders, 2008, 23, 329-342.	2.2	1,558
222	Cutâ€off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Movement Disorders, 2008, 23, 1546-1550.	2.2	117
223	Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Movement Disorders, 2008, 23, 1906-1912.	2.2	66
224	Cognitive and behavioral assessment in the early stages of neurodegenerative extrapyramidal syndromes. Archives of Gerontology and Geriatrics, 2008, 47, 53-61.	1.4	44
225	Prefrontal cortex and basal ganglia control access to working memory. Nature Neuroscience, 2008, 11, 103-107.	7.1	848
226	Nonâ€motor symptoms in Parkinson's disease. European Journal of Neurology, 2008, 15, 14-20.	1.7	524
227	The assessment of depression in Parkinson's disease. European Journal of Neurology, 2008, 15, 487-492.	1.7	25
228	To what extent does frontal type executive impairment affect coping strategies in Parkinson's disease?. European Journal of Neurology, 2008, 15, 1131-1134.	1.7	4
229	How Parkinson's Disease Affects Nonâ€verbal Communication and Language Processing. Language and Linguistics Compass, 2008, 2, 739-759.	1.3	30
230	Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Research - Neuroimaging, 2008, 163, 171-182.	0.9	102
231	Variability in the clinical expression of Parkinson's disease. Journal of the Neurological Sciences, 2008, 266, 197-203.	0.3	64
232	Effects of acute administration of the hydroalcoholic extract of mate tea leaves (llex paraguariensis) in animal models of learning and memory. Journal of Ethnopharmacology, 2008, 120, 465-473.	2.0	44
233	Effects of neostriatal 6-OHDA lesion on performance in a rat sequential reaction time task. Neuroscience Letters, 2008, 444, 212-216.	1.0	16
234	Les troubles anxiodépressifs dans la maladie de Parkinson: une revue de la littérature. Annales Medico-Psychologiques, 2008, 166, 85-92.	0.2	2
235	Fronto-striatal deficit in Parkinson's disease during semantic event sequencing. Neurobiology of Aging, 2008, 29, 397-407.	1.5	73
236	Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Parkinsonism and Related Disorders, 2008, 14, 239-242.	1.1	11

#	Article	IF	CITATIONS
237	Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: A clinical and FDOPA-PET study. Parkinsonism and Related Disorders, 2008, 14, 224-228.	1.1	25
238	The recognition of facial emotion expressions in Parkinson's disease. European Neuropsychopharmacology, 2008, 18, 835-848.	0.3	97
239	Clinical aspects of Parkinson dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
240	Serotonergic and dopaminergic modulation of attentional processes. Progress in Brain Research, 2008, 172, 517-542.	0.9	64
241	Planning and task management in Parkinson's disease: Differential emphasis in dual-task performance. Journal of the International Neuropsychological Society, 2008, 14, 257-65.	1.2	19
242	Prospective memory impairment in individuals with Parkinson's disease Neuropsychology, 2008, 22, 283-292.	1.0	72
244	Public Events and Flashbulb Memories in Parkinson's Disease. Behavioural Neurology, 2008, 19, 49-52.	1.1	2
245	Mental health in Parkinson's disease: Supporting patients and carers. British Journal of Neuroscience Nursing, 2009, 5, 253-259.	0.1	1
246	Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14664-14669.	3.3	75
247	Reduced Ventrolateral fMRI Response during Observation of Emotional Gestures Related to the Degree of Dopaminergic Impairment in Parkinson Disease. Journal of Cognitive Neuroscience, 2009, 21, 1321-1331.	1.1	48
248	Predictors of Health Status in Nondepressed and Nondemented Individuals with Parkinson's Disease. Archives of Clinical Neuropsychology, 2009, 24, 699-709.	0.3	7
249	Impaired control of the oculomotor reflexes in Parkinson's disease. Neuropsychologia, 2009, 47, 2909-2915.	0.7	28
250	Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Research, 2009, 1262, 109-114.	1.1	39
251	Cognitive motor processes: The role of motor imagery in the study of motor representations. Brain Research Reviews, 2009, 60, 306-326.	9.1	662
252	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurology, The, 2009, 8, 464-474.	4.9	1,367
253	Dopamine and impulse control disorders in Parkinson's disease. Annals of Neurology, 2008, 64, S93-S100.	2.8	120
254	Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open″abel study. Movement Disorders, 2009, 24, 277-282.	2.2	124
255	Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. Journal of Neural Transmission, 2009, 116, 1257-1266.	1.4	27

#	Article	IF	CITATIONS
256	Dopaminergic influence on rat tongue function and limb movement initiation. Experimental Brain Research, 2009, 194, 587-596.	0.7	24
257	Risk is in the Air. Annals of the New York Academy of Sciences, 2009, 1170, 629-636.	1.8	35
258	Addenbrooke's Cognitive Examination validation in Parkinson's disease. European Journal of Neurology, 2009, 16, 142-147.	1.7	78
259	Driving ability in Parkinson's disease: Current status of research. Neuroscience and Biobehavioral Reviews, 2009, 33, 223-231.	2.9	58
260	Valutazione neuropsicologica nella malattia di Parkinson. , 2009, , 81-97.		0
261	Modeling Parkinson's Disease: 50 Years Later. , 2009, , 1-12.		0
262	The impact of executive functions on verb production in patients with Parkinson's disease. Cortex, 2009, 45, 930-942.	1,1	92
263	Cognitive dysfunction in non-demented Parkinson's disease patients: Controlled and automatic behavior. Cortex, 2009, 45, 922-929.	1.1	56
264	Object naming and action-verb generation in Parkinson's disease: A fMRI study. Cortex, 2009, 45, 960-971.	1.1	103
265	Irony comprehension and theory of mind deficits in patients with Parkinson's disease. Cortex, 2009, 45, 972-981.	1.1	141
266	Physical exercise improves motor and short-term social memory deficits in reserpinized rats. Brain Research Bulletin, 2009, 79, 452-457.	1.4	54
267	Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism and Related Disorders, 2009, 15, 88-93.	1.1	155
268	Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects. Progress in Neurobiology, 2009, 88, 89-103.	2.8	92
269	Pupillometric findings in patients with Parkinson's disease and cognitive disorder. International Journal of Psychophysiology, 2009, 72, 97-101.	0.5	39
270	Cholinergic deficiency in Alzheimer's and Parkinson's disease: Evaluation with pupillometry. International Journal of Psychophysiology, 2009, 73, 143-149.	0.5	111
271	Nonâ€motor Function of the Midbrain Dopaminergic Neurons. , 2009, , 147-160.		2
272	Impaired verbal memory in Parkinson disease: relationship to prefrontal dysfunction and somatosensory discrimination. Behavioral and Brain Functions, 2009, 5, 49.	1.4	7
273	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPalGN cohort. Brain, 2009, 132, 2958-2969.	3.7	842

#	Article	IF	CITATIONS
274	Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review. CNS Neuroscience and Therapeutics, 2009, 15, 157-182.	1.9	33
275	The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations. Clinical Neuropharmacology, 2009, 32, 266-268.	0.2	19
276	Cognitive and Personality Features in Parkinson Disease: 2 Sides of the Same Coin?. Cognitive and Behavioral Neurology, 2009, 22, 258-263.	0.5	27
277	Rasagiline improves learning and memory in young healthy rats. Behavioural Pharmacology, 2010, 21, 278-282.	0.8	11
278	Rivastigmine for the treatment of Parkinson's disease dementia. Aging Health, 2010, 6, 277-284.	0.3	0
279	SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1128-1140.	3.3	21
280	Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. Journal of Neural Transmission, 2010, 117, 369-375.	1.4	49
281	Attentional Focus Modulated by Mesothalamic Dopamine: Consequences in Parkinson's Disease and Attention Deficit Hyperactivity Disorder. Cognitive Computation, 2010, 2, 31-49.	3.6	11
282	Single Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in C57BL/6 Mice Models Early Preclinical Phase of Parkinson's Disease. Neurotoxicity Research, 2010, 17, 114-129.	1.3	105
283	Neuroprotective Effect of PACAP on Translational Control Alteration and Cognitive Decline in MPTP Parkinsonian Mice. Neurotoxicity Research, 2010, 17, 142-155.	1.3	66
284	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurology, The, 2010, 9, 1200-1213.	4.9	753
285	Responsiveness to distracting stimuli, though increased in Parkinson's disease, is decreased in asymptomatic PINK1 and Parkin mutation carriers. Neuropsychologia, 2010, 48, 467-476.	0.7	21
286	Strategy instruction in Parkinson's disease: Influence on cognitive performance. Neuropsychologia, 2010, 48, 574-580.	0.7	16
287	From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease., 2010, 128, 229-273.		68
288	Spontaneous language production in bilingual Parkinson's disease patients: Evidence of greater phonological, morphological and syntactic impairments in native language. Brain and Language, 2010, 113, 84-89.	0.8	50
289	Computational models inform clinical science and assessment: An application to category learning in striatal-damaged patients. Journal of Mathematical Psychology, 2010, 54, 109-122.	1.0	3
290	Cognitive dysfunction in non-demented patients with Parkinson's disease. Annals of General Psychiatry, 2010, 9, S146.	1.2	1
291	Pathologic Correlates of Dementia in Individuals with Lewy Body Disease. Brain Pathology, 2010, 20, 654-659.	2.1	39

#	Article	IF	CITATIONS
292	Neuroimaging of Parkinson's disease., 2010, , 361-370.		0
293	Lewy Body and Parkinsonian Dementia. Deutsches Ärzteblatt International, 2010, 107, 684-91.	0.6	40
294	The Contribution of Neuroimaging for the Study of Cognitive Deficits in Parkinson's Disease. Clinical EEG and Neuroscience, 2010, 41, 76-81.	0.9	7
295	Pathology of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 132-154.	0.1	6
296	Characteristics of executive function impairment in Parkinson's disease patients without dementia. Journal of the International Neuropsychological Society, 2010, 16, 268-277.	1.2	141
297	Intact Reward Learning but Elevated Delay Discounting in Parkinson's Disease Patients With Impulsive-Compulsive Spectrum Behaviors. Neuropsychopharmacology, 2010, 35, 2155-2164.	2.8	159
298	Incidental Encoding Strategies Did Not Improve Contextual Memory in Parkinson's Disease Patients. Neurorehabilitation and Neural Repair, 2010, 24, 450-456.	1.4	14
299	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. Journal of the International Neuropsychological Society, 2010, 16, 867-876.	1.2	49
300	Enhanced frontal function in Parkinson's disease. Brain, 2010, 133, 225-233.	3.7	120
301	Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology, 2010, 74, 1416-1423.	1.5	151
302	The Neural Circuitry of Executive Functions in Healthy Subjects and Parkinson's Disease. Neuropsychopharmacology, 2010, 35, 70-85.	2.8	163
303	Associative Learning and CA3-CA1 Synaptic Plasticity Are Impaired in D1R Null, Drd1a-/- Mice and in Hippocampal siRNA Silenced Drd1a Mice. Journal of Neuroscience, 2010, 30, 12288-12300.	1.7	127
304	Effects of Caffeine in Parkinson's Disease: From Neuroprotection to the Management of Motor and Non-Motor Symptoms. Journal of Alzheimer's Disease, 2010, 20, S205-S220.	1.2	128
305	White matter pathways associated with working memory in normal aging. Cortex, 2010, 46, 474-489.	1.1	142
306	Overgeneral autobiographical memory in Parkinson's disease. Cortex, 2010, 46, 787-793.	1.1	20
307	Impaired emotion recognition in music in Parkinson's disease. Brain and Cognition, 2010, 74, 58-65.	0.8	28
308	Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task. Neurobiology of Learning and Memory, 2010, 94, 229-239.	1.0	16
309	Parkinson's Disease: Definition, Diagnosis, and Management. , 2010, , 405-412.		4

#	Article	IF	CITATIONS
310	Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease. Experimental Neurology, 2010, 226, 207-217.	2.0	43
311	Basal Ganglia Disorders in Genetic Models and Experimentally Induced Lesions. Neuromethods, 2010, , 91-112.	0.2	0
312	Memory function in patients with Parkinson's disease or subcortical lacunar infarcts evaluated by visual event-related potentials. , 2010 , , .		0
313	Striding Out With Parkinson Disease: Evidence-Based Physical Therapy for Gait Disorders. Physical Therapy, 2010, 90, 280-288.	1.1	173
314	Imaging cognitive and behavioral symptoms in Parkinson's disease. Expert Review of Neurotherapeutics, 2010, 10, 1827-1838.	1.4	18
315	Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease. Clinical Neurophysiology, 2011, 122, 2355-2364.	0.7	91
316	Age- and duration-dependent effects of MPTP on cortical serotonin systems. Neuroscience Letters, 2011, 504, 160-164.	1.0	7
317	Neuropsychiatric symptoms. , 2011, , 45-56.		1
318	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. CNS Neuroscience and Therapeutics, 2011, 17, 428-441.	1.9	61
319	Effects of a Multimodal Exercise Program on Clinical, Functional Mobility and Cognitive Parameters of Idiopathic Parkinson's Disease Patients. , 0, , .		3
320	Language Processing in Parkinson's Disease Patients Without Dementia., 2011,,.		6
321	Cognitive Dysfunction in Parkinson's Disease. , 2011, , .		4
322	Impact of External Cue Validity on Driving Performance in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-10.	0.6	10
323	Neuropsychological Deficits in Initial Parkinson's Disease. , 2011, , .		0
324	Neuropsychological Functions and SPECT Neuroimaging in Parkinson's Disease. , 0, , .		1
325	Cognitive Rehabilitation in Parkinson's Disease: Evidence from Neuroimaging. Frontiers in Neurology, 2011, 2, 82.	1.1	89
326	Sentence Comprehension and Its Association with Executive Functions in Patients with Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-15.	0.6	24
327	Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients. Journal of the International Neuropsychological Society, 2011, 17, 1158-1162.	1.2	12

#	Article	IF	CITATIONS
328	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited Neuropsychology, 2011, 25, 114-124.	1.0	88
329	Understanding verbal fluency in healthy aging, Alzheimer's disease, and Parkinson's disease Neuropsychology, 2011, 25, 210-225.	1.0	153
330	Psychometrically matched tasks evaluating differential fMRI activation during form and motion processing Neuropsychology, 2011, 25, 622-633.	1.0	8
331	A process-model based approach to prospective memory impairment in Parkinson's disease. Neuropsychologia, 2011, 49, 2166-2177.	0.7	128
332	De ziekte van Parkinson en stoornissen in taalverwerking: waar zit de knoop?. Neuropraxis, 2011, 15, 107-112.	0.1	1
333	Sleepwalking in Parkinson's disease: a questionnaire-based survey. Journal of Neurology, 2011, 258, 1261-1267.	1.8	16
334	Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease. Journal of Neural Transmission, 2011, 118, 1215-1225.	1.4	34
335	Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson's disease suffering from motor response fluctuations. Experimental Brain Research, 2011, 208, 169-179.	0.7	113
336	Subthalamic nucleus stimulation selectively improves motor and visual memory performance in Parkinson's disease. Movement Disorders, 2011, 26, 2019-2025.	2.2	15
337	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PDâ€MCI. Movement Disorders, 2011, 26, 1814-1824.	2.2	649
338	Correlates of Informal Caregiver Distress in Parkinson's Disease: A Meta-Analysis. Clinical Gerontologist, 2011, 34, 117-131.	1.2	30
339	Quantitative analysis of language production in Parkinson's disease using a cued sentence generation task. Clinical Linguistics and Phonetics, 2012, 26, 863-881.	0.5	20
340	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson's Disease. Frontiers in Neurology, 2012, 3, 159.	1.1	31
341	Depression in Parkinson's disease: diagnosis and management. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 331-334.	0.2	10
342	Gait patterns in parkinsonian patients with or without mild cognitive impairment. Movement Disorders, 2012, 27, 1536-1543.	2.2	66
343	Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease. Neuropsychologia, 2012, 50, 2506-2514.	0.7	26
344	Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behavioural Brain Research, 2012, 229, 208-215.	1.2	67
345	Effects of explicit prioritization on dual task walking in patients with Parkinson's disease. Gait and Posture, 2012, 35, 641-646.	0.6	62

#	Article	IF	Citations
346	Sleep disturbance in Parkinson disease. Journal of Clinical Gerontology and Geriatrics, 2012, 3, 53-61.	0.7	9
347	Dopaminergic modulation of neural correlates of working memory in Parkinson's Disease. Basal Ganglia, 2012, 2, 33-39.	0.3	4
348	Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. The Cochrane Library, 2014, 2014, CD006504.	1.5	224
349	The role of the right dorsolateral prefrontal cortex in the Tower of London task performance: repetitive transcranial magnetic stimulation study in patients with Parkinson's disease. Experimental Brain Research, 2012, 223, 251-257.	0.7	36
350	The influence of spatial working memory on ipsilateral remembered proprioceptive matching in adults with cerebral palsy. Experimental Brain Research, 2012, 223, 259-269.	0.7	22
351	Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. Expert Review of Medical Devices, 2012, 9, 71-83.	1.4	53
352	Role of Basal Ganglia Circuits in Resisting Interference by Distracters: A swLORETA Study. PLoS ONE, 2012, 7, e34239.	1,1	20
353	Frontostriatal Cognitive Staging in Parkinson's Disease. Parkinson's Disease, 2012, 2012, 1-8.	0.6	33
354	Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects. Parkinson's Disease, 2012, 2012, 1-15.	0.6	79
355	Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease. , 0, , .		1
356	Metacognitive Performance, the Tip-of-Tongue Experience, Is Not Disrupted in Parkinsonian Patients. Parkinson's Disease, 2012, 2012, 1-12.	0.6	4
357	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain, 2012, 135, 170-180.	3.7	149
358	Relationships between Cognitive Functions and Driving Behavior in Parkinson's Disease. European Neurology, 2012, 68, 98-107.	0.6	31
359	iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Experimental Neurology, 2012, 234, 499-505.	2.0	57
360	Efficacy of tailored computer-based neurorehabilitation for improvement of movement initiation in Parkinson's disease. Brain Research, 2012, 1452, 151-164.	1.1	25
361	Testing the contributions of striatal dopamine loss to the genesis of parkinsonian signs. Neurobiology of Disease, 2012, 47, 114-125.	2.1	17
362	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. Neuropsychologia, 2012, 50, 1980-1989.	0.7	53
363	Earlyâ€stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy. European Journal of Neurology, 2012, 19, 510-516.	1.7	28

#	Article	IF	CITATIONS
364	Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?. European Journal of Neuroscience, 2012, 35, 1894-1907.	1.2	46
365	Norepinephrine: the next therapeutics frontier for Parkinson's disease. Translational Neurodegeneration, 2012, 1, 4.	3.6	36
366	Intranasal Administration of Neurotoxicants in Animals: Support for the Olfactory Vector Hypothesis of Parkinson's Disease. Neurotoxicity Research, 2012, 21, 90-116.	1.3	76
367	Screening for DSMâ€IVâ€IR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale. International Journal of Geriatric Psychiatry, 2013, 28, 364-371.	1.3	9
368	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. Human Brain Mapping, 2013, 34, 1591-1604.	1.9	52
369	Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats. Pharmacology Biochemistry and Behavior, 2013, 110, 1-7.	1.3	54
370	Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology, 2013, 230, 345-352.	1.5	66
371	Characterization of cognitive and motor performance during dual-tasking in healthy older adults and patients with Parkinson's disease. Journal of Neurology, 2013, 260, 580-589.	1.8	82
372	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Reviews in the Neurosciences, 2013, 24, 267-78.	1.4	152
373	A Systematic Review of Impulse Control Disorders in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 105-138.	1.5	118
374	Idiopathic Parkinson's disease phenotype related to C9ORF72 repeat expansions: contribution of the neuropsychological assessment. BMC Research Notes, 2013, 6, 343.	0.6	5
375	Pattern of Executive Impairment in Mild to Moderate Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 36, 50-66.	0.7	17
376	User-centred design of a mobile self-management solution for Parkinson's disease., 2013,,.		28
377	Heterogeneity of Letter Fluency Impairment and Executive Dysfunction in Parkinson's Disease. Journal of the International Neuropsychological Society, 2013, 19, 986-994.	1.2	33
378	Obsessionality., 2013,, 31-43.		0
379	A complex dietary supplement augments spatial learning, brain mass, and mitochondrial electron transport chain activity in aging mice. Age, 2013, 35, 23-33.	3.0	19
380	Mechanisms of memory enhancement. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 37-53.	6.6	61
381	The temporal context of certainty–uncertainty modulates the subthalamic nucleus-mediated anticipatory responding. Behavioural Brain Research, 2013, 247, 40-47.	1.2	0

#	Article	IF	CITATIONS
382	The interaction between the dopaminergic forebrain projections and the medial prefrontal cortex is critical for memory of objects: Implications for Parkinson's disease. Experimental Neurology, 2013, 247, 373-382.	2.0	38
383	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and theÂUniversity of Washington. Alzheimer's and Dementia. 2013. 9. 609-614.	0.4	24
384	Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: A fMRI study. Brain and Language, 2013, 125, 324-329.	0.8	22
385	Joint principles of motor and cognitive dysfunction in Parkinson's disease. Neuropsychologia, 2013, 51, 1417-1425.	0.7	10
386	Impulse Control and Related Disorders in Parkinson's Disease. Neurodegenerative Diseases, 2013, 11, 63-71.	0.8	82
387	Sweet liking in patients with Parkinson's disease. Journal of the Neurological Sciences, 2013, 329, 17-22.	0.3	83
388	Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction. Journal of the Neurological Sciences, 2013, 329, 23-28.	0.3	61
389	Action-verb processing in Parkinson's disease: new pathways for motor–language coupling. Brain Structure and Function, 2013, 218, 1355-1373.	1.2	107
390	Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease. Brain Research, 2013, 1513, 103-116.	1.1	49
391	Grammatical deficits in bilingual Azari – Farsi patients with Parkinson's disease. Journal of Neurolinguistics, 2013, 26, 22-30.	0.5	16
392	Longer-term exposure to an intersection assistant: effects of ADAS use on intersection performance of drivers diagnosed with Parkinson's disease. International Journal of Human Factors and Ergonomics, 2013, 2, 223.	0.2	4
393	Eye movements during natural actions in patients with schizophrenia. Journal of Psychiatry and Neuroscience, 2013, 38, 317-324.	1.4	7
394	Frontostriatal and mediotemporal lobe contributions to implicit higher-order spatial sequence learning declines in aging and Parkinson's disease Behavioral Neuroscience, 2013, 127, 204-221.	0.6	19
395	Loss of asymmetric spine synapses in prefrontal cortex of motor-asymptomatic, dopamine-depleted, cognitively impaired MPTP-treated monkeys. International Journal of Neuropsychopharmacology, 2013, 16, 905-912.	1.0	18
396	Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 774-783.	0.9	199
397	Involvement of the Globus Pallidus in Behavioral Goal Determination and Action Specification. Journal of Neuroscience, 2013, 33, 13639-13653.	1.7	37
398	Cognitive Change in Newly-Diagnosed Patients with Parkinson's Disease: A 5-Year Follow-up Study. Journal of the International Neuropsychological Society, 2013, 19, 695-708.	1.2	74
399	Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 23-28.	0.9	78

#	Article	IF	CITATIONS
400	Erken Evre Parkinson Hastalığında Motor Olmayan Semptomların Değerlendirilmesi. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2013, 19, 97-103.	0.1	4
401	Autobiographical memory in Parkinson's disease: A retrieval deficit. Journal of Neuropsychology, 2013, 7, 164-178.	0.6	10
402	Representation of Spatial- and Object-Specific Behavioral Goals in the Dorsal Globus Pallidus of Monkeys during Reaching Movement. Journal of Neuroscience, 2013, 33, 16360-16371.	1.7	13
403	Working memory in Parkinson's disease: The effects of depression and side of onset of motor symptoms Neuropsychology, 2013, 27, 303-313.	1.0	13
405	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
406	Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia. Journal of Parkinson's Disease, 2013, 3, 69-76.	1.5	38
407	Impact of specific executive functions on driving performance in people with Parkinson's disease. Movement Disorders, 2013, 28, 1941-1948.	2.2	32
408	Executive dysfunction in Parkinson's disease and timing deficits. Frontiers in Integrative Neuroscience, 2013, 7, 75.	1.0	80
409	White Matter Hyperintensities in Parkinson's Disease: Do They Explain the Disparity between the Postural Instability Gait Difficulty and Tremor Dominant Subtypes?. PLoS ONE, 2013, 8, e55193.	1.1	60
410	Cortico-basal ganglia networks subserving goal-directed behavior mediated by conditional visuo-goal association. Frontiers in Neural Circuits, 2013, 7, 158.	1.4	34
411	Behavioral Phenotyping of Parkin-Deficient Mice: Looking for Early Preclinical Features of Parkinson's Disease. PLoS ONE, 2014, 9, e114216.	1.1	94
412	Influence of Hypertension on Neurocognitive Domains in Nondemented Parkinson's Disease Patients. Parkinson's Disease, 2014, 2014, 1-10.	0.6	14
413	Dopamine and the Biology of Creativity: Lessons from Parkinson $\tilde{A}^{\hat{a}}$, $\tilde{A}^{\hat{a}}$, $\tilde{A}^{\hat{a}}$ Disease. Frontiers in Neurology, 2014, 5, 55.	1.1	42
414	Corpus Striatum. , 2014, , 869-871.		0
415	Sex Differences Distinguish Intracortical Glutamate Receptor-Mediated Regulation of Extracellular Dopamine Levels in the Prefrontal Cortex of Adult Rats. Cerebral Cortex, 2016, 26, bhu222.	1.6	27
416	Language recovery and evidence of residual deficits after nonthalamic subcortical stroke: AÂ1Âyear follow-up study. Journal of Neurolinguistics, 2014, 32, 16-30.	0.5	5
417	Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations. Journal of Neurology, 2014, 261, 2401-2410.	1.8	87
418	Connectivity of the subthalamic nucleus and globus pallidus pars interna to regions within the speech network: A meta-analytic connectivity study. Human Brain Mapping, 2014, 35, 3499-3516.	1.9	29

#	Article	IF	CITATIONS
419	Conversion between Miniâ€Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scaleâ€2 scores in Parkinson's disease. Movement Disorders, 2014, 29, 1809-1815.	2.2	86
420	Apathy in Parkinson's Disease: An Electrophysiological Study. Neurology Research International, 2014, 2014, 1-9.	0.5	18
421	Nonlinear Dose-Dependent Impact of D1 Receptor Activation on Motor Cortex Plasticity in Humans. Journal of Neuroscience, 2014, 34, 2744-2753.	1.7	73
422	Levodopa inhibits habit-learning in Parkinson's disease. Journal of Neural Transmission, 2014, 121, 147-151.	1.4	12
423	Patients with Parkinson׳s disease are less affected than healthy persons by relevant response-unrelated features in visual search. Neuropsychologia, 2014, 62, 38-47.	0.7	5
424	Interaction of Curcumin with Manganese May Compromise Metal and Neurotransmitter Homeostasis in the Hippocampus of Young Mice. Biological Trace Element Research, 2014, 158, 399-409.	1.9	12
425	Application of PEDOT NT Microelectrodes for Neurotransmitter Sensing. Electroanalysis, 2014, 26, 548-555.	1.5	31
426	Words in motion: Motor-language coupling in Parkinson's disease. Translational Neuroscience, 2014, 5, .	0.7	45
427	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. Biological Psychiatry, 2014, 75, 701-710.	0.7	56
428	A meta-analysis and meta-regression of serial reaction time task performance in Parkinson's disease Neuropsychology, 2014, 28, 945-958.	1.0	56
429	Resting State Functional Connectivity is Associated with Cognitive Dysfunction in Non-Demented People with Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 453-465.	1.5	52
430	Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's Disease. The Cochrane Library, 0, , .	1.5	7
431	Executive function deficits and glutamatergic protein alterations in a progressive 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine mouse model of Parkinson's disease. Journal of Neuroscien Research, 2015, 93, 1849-1864.	C ∉. 3	16
432	Accommodation of workers with chronic neurologic disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 131, 505-516.	1.0	1
433	Hypometabolism in Posterior and Temporal Areas of the Brain is Associated with Cognitive Decline in Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 569-574.	1.5	37
434	Gestures make memories, but what kind? Patients with impaired procedural memory display disruptions in gesture production and comprehension. Frontiers in Human Neuroscience, 2014, 8, 1054.	1.0	18
435	Neuroimaging studies of striatum in cognition part II: Parkinson's disease. Frontiers in Systems Neuroscience, 2015, 9, 138.	1.2	33
436	Exploring Biological Motion Processing in Parkinson's Disease Using Temporal Dilation. PLoS ONE, 2015, 10, e0138502.	1.1	10

#	Article	IF	CITATIONS
437	Building a Framework for a Dual Task Taxonomy. BioMed Research International, 2015, 2015, 1-10.	0.9	138
438	Association between Community Ambulation Walking Patterns and Cognitive Function in Patients with Parkinson's Disease: Further Insights into Motor-Cognitive Links. Parkinson's Disease, 2015, 2015, 1-11.	0.6	16
439	Syntax, action verbs, action semantics, and object semantics in Parkinson's disease: Dissociability, progression, and executive influences. Cortex, 2015, 69, 237-254.	1.1	147
440	Modified <scp>S</scp> ix <scp>E</scp> lements <scp>T</scp> est: <scp>E</scp> arlier diagnosis of the correlation between motor and executive dysfunction in <scp>P</scp> arkinson's disease without dementia. Neurology and Clinical Neuroscience, 2015, 3, 209-214.	0.2	3
441	Nitrosative and cognitive effects of chronic l-DOPA administration in rats with intra-nigral 6-OHDA lesion. Neuroscience, 2015, 290, 492-508.	1.1	20
442	Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease. Brain Imaging and Behavior, 2015, 9, 619-638.	1.1	28
443	Visual Attention and Saccadic Oculomotor Control in Parkinson's Disease. European Neurology, 2015, 73, 283-293.	0.6	17
444	SubtalamotomÃa bilateral diferida en enfermedad de Parkinson: evaluación motora, cognitiva y conductual. Neurologia Argentina, 2015, 7, 67-75.	0.1	3
445	Parkinson's disease dementia: a neural networks perspective. Brain, 2015, 138, 1454-1476.	3.7	333
446	Disentangling the relationship between cognitive estimation abilities and executive functions: a study on patients with Parkinson's disease. Neurological Sciences, 2015, 36, 1425-1429.	0.9	12
447	Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: A model for early Parkinson's disease. Neuroscience Research, 2015, 92, 71-79.	1.0	10
448	Longer-Term Effects of ADAS Use on Speed and Headway Control in Drivers Diagnosed With Parkinson's Disease. Traffic Injury Prevention, 2015, 16, 10-16.	0.6	11
449	Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism. Stem Cell Reports, 2015, 5, 791-804.	2.3	58
450	Cognition and Depression Following Deep Brain Stimulation of the Subthalamic Nucleus and Globus Pallidus Pars Internus in Parkinson's Disease: A Meta-Analysis. Neuropsychology Review, 2015, 25, 439-454.	2.5	149
451	Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. Expert Review of Neurotherapeutics, 2015, 15, 1231-1240.	1.4	22
452	Motor loop dysfunction causes impaired cognitive sequencing in patients suffering from Parkinson's disease. Neuropsychologia, 2015, 77, 409-420.	0.7	14
453	Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention – A Comparison with Parkinson's Disease. Neuropsychology Review, 2015, 25, 424-438.	2.5	42
454	NK3 receptor agonism reinstates temporal order memory in the hemiparkinsonian rat. Behavioural Brain Research, 2015, 285, 208-212.	1.2	13

#	ARTICLE	IF	Citations
455	Telerehabilitation in Parkinson's disease: Influence of cognitive status. Dementia E Neuropsychologia, 2016, 10, 327-332.	0.3	22
456	The Chronic Exercise–Cognition Interaction and Parkinson Disease. , 2016, , 321-343.		2
457	Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study. Parkinson's Disease, 2016, 2016, 1-9.	0.6	3
458	Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. Frontiers in Aging Neuroscience, 2016, 8, 4.	1.7	23
459	Apathy, Novelty Processing, and the P3 Potential in Parkinson's Disease. Frontiers in Neurology, 2016, 7, 95.	1.1	12
460	Probing the Role of Medication, DBS Electrode Position, and Antidromic Activation on Impulsivity Using a Computational Model of Basal Ganglia. Frontiers in Human Neuroscience, 2016, 10, 450.	1.0	8
461	Pramipexole Impairs Stimulus-Response Learning in Healthy Young Adults. Frontiers in Neuroscience, 2016, 10, 374.	1.4	20
462	Quiet connections: Reduced frontoâ€ŧemporal connectivity in nondemented Parkinson's Disease during working memory encoding. Human Brain Mapping, 2016, 37, 3224-3235.	1.9	41
463	The effect of interference on temporal order memory in individuals with Parkinson's disease. Brain and Cognition, 2016, 107, 30-36.	0.8	3
464	Neuropsychological correlates of Pisa syndrome in patients with Parkinson's disease. Acta Neurologica Scandinavica, 2016, 134, 101-107.	1.0	23
465	Facilitating effects of deep brain stimulation on feedback learning in Parkinson's disease. Behavioural Brain Research, 2016, 313, 88-96.	1.2	3
466	Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson's Disease and MPTP. Behavior Genetics, 2016, 46, 228-241.	1.4	17
467	Event-related potentials and cognition in Parkinson's disease: An integrative review. Neuroscience and Biobehavioral Reviews, 2016, 71, 691-714.	2.9	77
468	Periodic Limb Movements in Sleep are Associated with Greater Cognitive Decline in Older Men without Dementia. Sleep, 2016, 39, 1807-1810.	0.6	34
469	Use of the Montreal Cognitive Assessment and Alzheimer's Diseaseâ€8 as cognitive screening measures in Parkinson's disease. International Journal of Geriatric Psychiatry, 2016, 31, 264-272.	1.3	19
470	Deficits in task-set maintenance and execution networks in Parkinson's disease. Brain Structure and Function, 2016, 221, 1413-1425.	1.2	39
471	Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 249-258.	4.9	257
472	Abnormal fronto-striatal functional connectivity in Parkinson's disease. Neuroscience Letters, 2016, 613, 66-71.	1.0	23

#	Article	IF	CITATIONS
473	Two sides of the same coin: Impairment in perception of temporal components of rhythm and cognitive functions in Parkinson's disease. Basal Ganglia, 2016, 6, 63-70.	0.3	14
474	Self-awareness of memory impairment in Parkinson's disease: a review of the literature. Working With Older People, 2016, 20, 57-64.	0.2	2
475	User interface design guidelines for smartphone applications for people with Parkinson's disease. Universal Access in the Information Society, 2016, 15, 659-679.	2.1	39
476	Dopaminergic Modulation of Cognitive Preparation for Overt Reading: Evidence from the Study of Genetic Polymorphisms. Cerebral Cortex, 2016, 26, 1539-1557.	1.6	6
477	Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease. Molecular Neurobiology, 2017, 54, 1513-1530.	1.9	11
478	Are Parkinson's Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study. Journal of the International Neuropsychological Society, 2017, 23, 322-331.	1.2	18
479	Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support. Neurochemistry International, 2017, 106, 94-100.	1.9	132
480	Dopaminergic modulation of performance monitoring in Parkinson's disease: An event-related potential study. Scientific Reports, 2017, 7, 41222.	1.6	21
481	A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review. Bulletin of the Menninger Clinic, 2017, 81, 53-105.	0.3	15
482	The effect of active video games on cognitive functioning in clinical and non-clinical populations: A meta-analysis of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 2017, 78, 34-43.	2.9	273
483	The many facets of motor learning and their relevance for Parkinson's disease. Clinical Neurophysiology, 2017, 128, 1127-1141.	0.7	100
484	Dual tasking in Parkinson's disease: Cognitive consequences while walking Neuropsychology, 2017, 31, 613-623.	1.0	44
485	Identification and intensity of disgust: Distinguishing visual, linguistic and facial expressions processing in Parkinson disease. Behavioural Brain Research, 2017, 330, 30-36.	1.2	12
486	Early-onset mild cognitive impairment in Parkinson's disease: Altered corticopetal cholinergic network. Scientific Reports, 2017, 7, 2381.	1.6	15
487	Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. Archives of Clinical Neuropsychology, 2017, 32, 786-801.	0.3	27
488	Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study. Journal of Neurology, 2017, 264, 2149-2157.	1.8	41
489	Comparative Patient Satisfaction and Feasibility of a Pilot Parkinson's Disease Enrichment Program. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 253-260.	1.2	3
490	Dopaminergic Modulation of Biological Motion Perception in patients with Parkinson's disease. Scientific Reports, 2017, 7, 10159.	1.6	5

#	Article	IF	CITATIONS
491	Losing ground: Frontostriatal atrophy disrupts language embodiment in Parkinson's and Huntington's disease. Neuroscience and Biobehavioral Reviews, 2017, 80, 673-687.	2.9	83
492	Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease. Npj Parkinson's Disease, 2017, 3, 2.	2.5	63
493	Which are the critical parameters assessing the driving performance of drivers with cerebral diseases? A literature review. Transportation Research Procedia, 2017, 25, 4338-4354.	0.8	3
494	Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice. Behavioural Brain Research, 2017, 333, 150-160.	1.2	27
495	Impulse Control and Related Disorders in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 679-717.	0.9	195
496	Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease. Chinese Medical Journal, 2017, 130, 2726-2731.	0.9	9
497	Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease. PLoS ONE, 2017, 12, e0181349.	1.1	23
498	Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson& Disease and Treatment, 2017, Volume 13, 2719-2726.	1.0	10
499	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. Clinical Neurophysiology, 2018, 129, 766-782.	0.7	45
500	Feature-based information filtering in visual working memory is impaired in Parkinson's disease. Neuropsychologia, 2018, 111, 317-323.	0.7	9
501	The role of aquaporin-4 in synaptic plasticity, memory and disease. Brain Research Bulletin, 2018, 136, 118-129.	1.4	97
502	Physiological substrates of executive functioning: a systematic review of the literature. ADHD Attention Deficit and Hyperactivity Disorders, 2018, 10, 1-20.	1.7	23
503	Got Rhythm? Better Inhibitory Control Is Linked with More Consistent Drumming and Enhanced Neural Tracking of the Musical Beat in Adult Percussionists and Nonpercussionists. Journal of Cognitive Neuroscience, 2018, 30, 14-24.	1.1	27
504	Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments. Neurological Sciences, 2018, 39, 215-223.	0.9	81
505	Effects of chronic aspartame consumption on MPTP-induced Parkinsonism in male and female mice. Archives of Physiology and Biochemistry, 2018, 124, 292-299.	1.0	8
506	Exploring the association of the Comprehensive Trail Making Test with driving indexes in patients with Parkinson's disease. Transportation Research Part F: Traffic Psychology and Behaviour, 2018, 59, 535-544.	1.8	5
507	Improving and integrating care for Parkinson's disease. Nursing and Residential Care, 2018, 20, 615-620.	0.1	1
508	Measuring executive dysfunction in Parkinson's disease: Reliability and validity of the Spanish version of Frontal Assessment Battery (FAB-E). PLoS ONE, 2018, 13, e0207698.	1.1	19

#	Article	IF	CITATIONS
509	Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease. Human Brain Mapping, 2018, 39, 5014-5027.	1.9	13
510	The Role of Atomoxetine for Parkinson Disease–Related Executive Dysfunction. Journal of Clinical Psychopharmacology, 2018, 38, 627-631.	0.7	22
511	Loudness Perception of Pure Tones in Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2018, 61, 1487-1496.	0.7	12
512	Short-term temporal memory in idiopathic and Parkin-associated Parkinson's disease. Scientific Reports, 2018, 8, 7637.	1.6	10
513	The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors. Neurotoxicity Research, 2018, 34, 808-819.	1.3	21
514	Psychological functioning in Parkinson's disease post-deep brain stimulation: Self-regulation and executive functioning. Journal of Psychosomatic Research, 2018, 111, 42-49.	1.2	5
516	Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease. Behavioral Sciences (Basel, Switzerland), 2018, 8, 51.	1.0	11
517	Selection Processing in Noun and Verb Production in Left- and Right-Sided Parkinson's Disease Patients. Frontiers in Psychology, 2018, 9, 1241.	1.1	14
518	Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease. Neurology, 2019, 93, e766-e777.	1.5	45
519	Altered Global Synchronizations in Patients With Parkinson's Disease: A Resting-State fMRI Study. Frontiers in Aging Neuroscience, 2019, 11, 139.	1.7	21
520	Study on Usefulness of Smartphone Applications for the People with Parkinson's. Lecture Notes in Computer Science, 2019, , 281-299.	1.0	0
521	Accelerated forgetting and verbal memory consolidation process in idiopathic nondement Parkinson's disease. Journal of Clinical Neuroscience, 2019, 70, 208-213.	0.8	12
522	Pre-stimulus beta power modulation during motor sequence learning is reduced in 'Parkinson's disease. Neurolmage: Clinical, 2019, 24, 102057.	1.4	6
523	Subjective judgments of rhythmic complexity in Parkinson's disease: Higher baseline, preserved relative ability, and modulated by tempo. PLoS ONE, 2019, 14, e0221752.	1.1	2
524	Transcranial direct current stimulation enhances theory of mind in Parkinson's disease patients with mild cognitive impairment: a randomized, double-blind, sham-controlled study. Translational Neurodegeneration, 2019, 8, 1.	3.6	59
525	<p>Affective theory of mind in Parkinson's disease: the effect of cognitive performance</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2521-2535.	1.0	27
526	Eye tracking – The overlooked method to measure cognition in neurodegeneration?. Neuropsychologia, 2019, 133, 107191.	0.7	40
527	The correlation between possible RBD and cognitive function in Parkinson's disease patients in China. Annals of Clinical and Translational Neurology, 2019, 6, 848-853.	1.7	16

#	Article	IF	CITATIONS
528	Dopamine Depletion Affects Vocal Acoustics and Disrupts Sensorimotor Adaptation in Songbirds. ENeuro, 2019, 6, ENEURO.0190-19.2019.	0.9	13
529	Memory, subjective memory and motor functioning in non-demented elders with and without Parkinson's disease. Europe's Journal of Psychology, 2019, 15, 404-420.	0.6	3
530	A Review of Cognitive Outcomes Across Movement Disorder Patients Undergoing Deep Brain Stimulation. Frontiers in Neurology, 2019, 10, 419.	1.1	47
531	The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: Two meta-analyses. Journal of Psychosomatic Research, 2019, 122, 43-51.	1.2	45
532	Attenuated NoGo-related beta desynchronisation and synchronisation in Parkinson's disease revealed by magnetoencephalographic recording. Scientific Reports, 2019, 9, 7235.	1.6	16
533	Central fatigue and attentional processing in Parkinson's disease: An event-related potentials study. Clinical Neurophysiology, 2019, 130, 692-700.	0.7	20
534	Improved Automatic Morphology-Based Classification of Parkinson's Disease and Progressive Supranuclear Palsy. Clinical Neuroradiology, 2019, 29, 605-614.	1.0	5
535	Impulse Control Disorders in Parkinson's Disease. American Journal of Psychiatry, 2019, 176, 5-11.	4.0	31
536	Considerations on Effective Feedback in Computerized Speech Training for Dysarthric Speakers. Telemedicine Journal and E-Health, 2019, 25, 351-358.	1.6	11
537	Highlighting the goals for Parkinson's care: commentary on NICE Guidelines for Parkinson's in Adults (NG71). Age and Ageing, 2019, 48, 323-326.	0.7	4
538	Limitations of the rat medial forebrain lesion model to study prefrontal cortex mediated cognitive tasks in Parkinson's disease. Brain Research, 2019, 1702, 105-113.	1.1	13
539	Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease. Neurolmage, 2019, 190, 94-106.	2.1	17
540	Cognitive Impairments and Self-Reported Sleep in Early-Stage Parkinson's Disease with Versus without Probable REM Sleep Behavior Disorder. Brain Sciences, 2020, 10, 9.	1.1	12
541	Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders. International Journal of Molecular Sciences, 2020, 21, 4918.	1.8	10
542	Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinson's Disease: A Review. Molecules, 2020, 25, 3926.	1.7	46
543	Cognitive flexibility deficits in rats with dorsomedial striatal 6-hydroxydopamine lesions tested using a three-choice serial reaction time task with reversal learning. NeuroReport, 2020, 31, 1055-1064.	0.6	3
544	Uncinate fasciculus and word selection processing in Parkinson's disease. Neuropsychologia, 2020, 146, 107504.	0.7	12
545	The Figure-of-8 Walk Test used to detect the loss of motor skill in walking among persons with Parkinson's disease. Physiotherapy Theory and Practice, 2022, 38, 552-560.	0.6	6

#	ARTICLE	IF	CITATIONS
546	Arterial spin labeling detects perfusion patterns related to motor symptoms in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 76, 21-28.	1.1	10
547	Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. The Cochrane Library, 2020, 2020, CD011961.	1.5	46
548	Dopaminergic afferents from midbrain to dorsolateral bed nucleus of stria terminalis inhibit release and expression of corticotropinâ€releasing hormone in paraventricular nucleus. Journal of Neurochemistry, 2020, 154, 218-234.	2.1	6
549	Enhanced Obstacle Contrast to Promote Visual Scanning in Fallers with Parkinson's Disease: Role of Executive Function. Neuroscience, 2020, 436, 82-92.	1.1	1
550	Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment. Parkinson's Disease, 2020, 2020, 1-11.	0.6	49
551	Music-based physical therapy in Parkinson's disease: An approach based on international Classification of Functioning, Disability and Health. Journal of Bodywork and Movement Therapies, 2021, 26, 524-529.	0.5	6
552	Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson's disease. Journal of Neuropsychology, 2021, 15, 253-273.	0.6	4
553	Inefficient resource allocation is associated with reduced alpha activity in parietal regions in individuals with Parkinson's disease. European Journal of Neuroscience, 2021, 53, 1225-1237.	1.2	4
554	Implicit sequence learning in individuals with Parkinson's disease: The added value of using an ocular version of the serial reaction time (O-SRT) task. Brain and Cognition, 2021, 147, 105654.	0.8	4
555	Clock-Drawing Tasks as Predictive Measurements for Disease Classification Among Patients With Parkinson's Disease and Essential Tremor. Cureus, 2021, 13, e13239.	0.2	2
556	Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control. Cells, 2021, 10, 735.	1.8	88
557	Laterality in Parkinson's disease: A neuropsychological review. Applied Neuropsychology Adult, 2023, 30, 126-140.	0.7	6
558	Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents. Biomedicines, 2021, 9, 684.	1.4	14
559	Plasma total tau predicts executive dysfunction in Parkinson's disease. Acta Neurologica Scandinavica, 2022, 145, 30-37.	1.0	10
560	Frontoparietal network resilience is associated with protection against cognitive decline in Parkinson's disease. Communications Biology, 2021, 4, 1021.	2.0	14
561	Driving and Parkinson's Disease: A Survey of the Patient's Perspective. Journal of Parkinson's Disease, 2022, 12, 465-471.	1.5	1
562	Concomitant improvement in anti-saccade success rate and postural instability gait difficulty after rTMS treatment for Parkinson's disease. Scientific Reports, 2021, 11, 2472.	1.6	4
563	Modeling Nonmotor Symptoms of Parkinson's Disease in Genetic Mouse Models. Advances in Behavioral Biology, 2009, , 483-491.	0.2	3

#	Article	IF	Citations
564	What is the Influence of Subthalamic Nucleus Stimulation on the Limbic Loop?. , 2001, , 333-340.		5
565	Cortico-Subcortical Dynamics in ParkinsonÂįs Disease., 2009,,.		3
566	Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. , 2006, , 123-132.		26
567	PD-related psychosis: pathophysiology with therapeutical strategies. , 2006, , 31-37.		17
568	FDG-PET study of the bilateral subthalamic nucleus stimulation effects on the regional cerebral metabolism in advanced Parkinson disease., 2006, 99, 51-54.		11
569	Deep brain stimulation for movement disorders and its neuropsychological implications. Acta Neurochirurgica Supplementum, 2008, 101, 9-12.	0.5	9
570	Cortico-Striatal, Cognitive-Motor Interactions Underlying Complex Movement Control Deficits. Innovations in Cognitive Neuroscience, 2016, , 117-134.	0.3	1
571	Differential executive control impairments in early Parkinson's disease. Journal of Neural Transmission Supplementum, 2004, , 39-51.	0.5	41
572	Corpus Striatum. , 2003, , 774-777.		2
573	Dementias. , 2012, , 1534-1582.		4
574	Neurologic Disorders Associated with Gastrointestinal Diseases and Nutritional Deficiencies. , 2012, , 1821-1866.		1
578	Recognition memory impairment in Parkinson's disease: power and meta-analyses. Neuropsychology, 2000, 14, 233-46.	1.0	49
579	The effects of integrated single- and dual-task training on automaticity and attention allocation in Parkinson's disease: A secondary analysis from a randomized trial Neuropsychology, 2019, 33, 147-156.	1.0	19
580	Interaction between cognition and gait in patients with Parkinson's disease. , 2015, , 91-110.		1
581	Mental disorders in movement disorders. Current Opinion in Psychiatry, 1998, 11, 315-319.	3.1	1
582	Psychiatric complications in Parkinson disease. American Journal of Geriatric Psychiatry, 2005, 13, 844-51.	0.6	68
583	Levodopa Facilitates Prefrontal Cortex Activation During Dual Task Walking in Parkinson Disease. Neurorehabilitation and Neural Repair, 2020, 34, 589-599.	1.4	30
584	Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology, 1999, 53, 1373-1373.	1.5	74

#	Article	IF	CITATIONS
585	Executive Functioning in Daily Life in Parkinson's Disease: Initiative, Planning and Multi-Task Performance. PLoS ONE, 2011, 6, e29254.	1.1	43
586	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia. PLoS ONE, 2012, 7, e48783.	1.1	37
587	Diminished Activation of Motor Working-Memory Networks in Parkinson's Disease. PLoS ONE, 2013, 8, e61786.	1.1	29
588	Psychotic symptoms in Parkinson's disease: pathophysiology and management. Expert Opinion on Drug Safety, 2004, 3, 209-20.	1.0	6
589	Attention and information acquisition: Comparison of mouse-click with eye-movement attention tracking. Journal of Eye Movement Research, 2018, 11 , .	0.5	11
590	Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson's disease: a Complete Review. , 2017, 1, 001-026.		8
591	Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease. US Neurology, 2011, 07, 100.	0.2	17
592	Neuropsychological aspects. , 2013, , 144-170.		2
593	Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience, 2016, 18, 99-107.	1.8	15
594	Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. Behavioural Neurology, 1995, 8, 15-22.	1.1	45
596	The Cardiovascular and Cerebrovascular Effects on Cognition in Persons with Parkinson's Disease: A Systematic Review of the Literature. Advances in Parkinson S Disease, 2015, 04, 28-42.	0.2	2
597	Cognition and Gait Disturbances in Parkinson's Disease. , 0, , .		1
598	Effects of Mental Flexibility and Motor Dysfunction on Cognitive Performance in Patients With Parkinson's Disease. Archives of Neuroscience, 2015, 2, .	0.1	6
599	Psychiatric complications in Parkinson's disease. , 2000, , 291-302.		9
600	Dopamine and Glutamate in Motor and Cognitive Symptoms of Parkinson's Disease. , 2005, , 523-535.		0
602	Presymptomatic and Symptomatic Stages of Intracerebral Inclusion Body Pathology in Idiopathic Parkinson's Disease. , 2005, , 475-502.		0
604	Genetic Models of Familial Parkinson's Disease. , 2008, , 225-236.		0
605	Behavioural Correlates of Cognitive Skill Learning in Parkinson's Disease. The Open Behavioral Science Journal, 2008, 2, 1-12.	0.8	0

#	Article	IF	CITATIONS
606	Cognitive Deficits in Parkinson's Disease. , 2009, , 1-15.		0
607	Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders., 2009,, 17-54.		0
608	I disturbi neuropsicologici nella malattia di Parkinson. , 2009, , 29-52.		0
609	Effects of dopamine depletion on reward-seeking behavior. , 2009, , 271-289.		0
612	Mesothalamic Dopaminergic Activity: Implications in Sleep Alterations in Parkinson's Disease., 0,,.		0
613	Impairments of attention functions in the patients with Machado-Joseph disease. Higher Brain Function Research, 2012, 32, 269-277.	0.0	0
614	Towards a Memristor Model Library in Modelica. , 2012, , .		3
615	Major Anatomical Structures. , 2013, , 131-205.		0
616	Management of psychosis and dementia., 2013,, 192-224.		1
617	Subcortical and Limbic Attentional Influences. , 2014, , 381-428.		0
618	Dissociation between categorization and recognition in the Alzheimer's and Parkinson's disease patients. Korean Journal of Cognitive and Biological Psychology, 2013, 25, 311-327.	0.0	0
619	Dopaminergic Neurons in Parkinson's Disease. , 2014, , 753-788.		5
620	Geriatrische Syndrome: Kognition. , 2014, , 1-11.		0
621	Subcortical Movement Disorders I. , 1995, , 290-311.		0
623	Neuropsychological Features of Mild Cognitive Impairment in Parkinson's Disease: A Critical Review of the Literature Journal of Aging and Gerontology, 2014, 2, 100-114.	0.4	0
624	Challenges & Diagnosed with Rare Movement Disorders. Qualitative Research with Persons Diagnosed with Rare	0.1	0
625	Mood Disorder in Parkinson's Disease. Nihon Ika Daigaku Igakkai Zasshi, 2016, 12, 78-85.	0.0	0
627	Subcortical Involvement in Formulaic Language: Studies on Bilingual Individuals With Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2020, 63, 4029-4045.	0.7	3

#	Article	IF	CITATIONS
629	The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders. Movement Disorders, 2020, 35, 2150-2155.	2.2	5
630	Intact learning of artificial grammars and intact category learning by patients with Parkinson's disease. Behavioral Neuroscience, 1999, 113, 235-42.	0.6	61
631	Cognitive impairment and dementia in patients with Parkinson disease. Current Topics in Medicinal Chemistry, 2009, 9, 903-12.	1.0	58
633	Mild cognitive impairment in Parkinson's disease. Minerva Medica, 2011, 102, 441-59.	0.3	113
634	Cognitive impairments in Parkinson's disease: Evidence from an Iranian population. Iranian Journal of Neurology, 2012, 11, 151-4.	0.5	1
636	Striatal dopamine correlates to memory and attention in Parkinson's disease. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 10-19.	1.0	1
637	Disembodying language: Actionality does not account for verb processing deficits in Parkinson's disease. Journal of Neurolinguistics, 2022, 61, 101040.	0.5	8
638	Functional neuroanatomy of cognition in Parkinson's disease. Progress in Brain Research, 2022, 269, 289-307.	0.9	0
639	Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease. Progress in Brain Research, 2022, 269, 309-343.	0.9	10
640	Preface. Progress in Brain Research, 2022, 269, xxi-xxvi.	0.9	0
641	Profile of cognitive impairment in lateâ€stage Parkinson's disease. Brain and Behavior, 2022, 12, e32537.	1.0	5
642	Therapeutic Devices for Motor Symptoms in Parkinson's Disease: Current Progress and a Systematic Review of Recent Randomized Controlled Trials. Frontiers in Aging Neuroscience, 2022, 14, 807909.	1.7	4
643	Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease. Drug Metabolism and Personalized Therapy, 2022, 37, 329-336.	0.3	7
644	Mapping Actuarial Criteria for Parkinson's Disease-Mild Cognitive Impairment onto Data-Driven Cognitive Phenotypes. Brain Sciences, 2022, 12, 54.	1.1	4
650	Cognition and emotion in different stages and subtypes of Parkinson's disease. Journal of Neurology, 2000, 247, 114-121.	1.8	43
651	Concept formation and concept shifting in frontal lesion and Parkinson's disease patients assessed with the California Card Sorting Test. Neuropsychology, 1999, 13, 135-43.	1.0	20
652	Quantitative modeling of visual attention processes in patients with Parkinson's disease: effects of stimulus integrality on selective attention and dimensional integration. Neuropsychology, 1999, 13, 206-22.	1.0	17
653	The effects of target and distractor familiarity on visual search in de novo Parkinson's disease patients: latent inhibition and novel pop-out. Neuropsychology, 1999, 13, 415-23.	1.0	11

#	ARTICLE	IF	CITATIONS
655	Frontal cognitive function and memory in Parkinson's disease: toward a distinction between prospective and declarative memory impairments?. Behavioural Neurology, 1995, 8, 59-74.	1.1	10
656	Developing Predictor Models of Postoperative Verbal Fluency After Deep Brain Stimulation Using Preoperative Neuropsychological Assessment. Neurosurgery, 2022, Publish Ahead of Print, .	0.6	0
657	Multifunctional Microcoaxial Fibers for Electrochemical, Optical and Spectroelectrochemical Sensing. SSRN Electronic Journal, 0, , .	0.4	0
658	Speech pauses and gestural holds in Parkinson's disease., 0, , .		8
659	Compensatory movement strategies differentially affect attention allocation and gait parameters in persons with Parkinsonâ \in ^{Ms} disease. Frontiers in Human Neuroscience, 0, 16, .	1.0	4
660	Prediction of Cognitive Degeneration in Parkinson's Disease Patients Using a Machine Learning Method. Brain Sciences, 2022, 12, 1048.	1.1	0
661	Preclinical (premotor) Parkinson's disease. Journal of Neurology, 2000, 247, 103-109.	1.8	54
662	Cognitive Function and Postural Control Strategies in Relation to Disease Progression in Patients with Parkinson's Disease. International Journal of Environmental Research and Public Health, 2022, 19, 12694.	1.2	2
663	Genetic variation in the dopamine system is associated with mixedâ€strategy decisionâ€making in patients with Parkinson's disease. European Journal of Neuroscience, 2023, 58, 4523-4544.	1.2	0
664	Diagnosis and Treatment of Tremor in Parkinson's Disease Using Mechanical Devices. Life, 2023, 13, 78.	1.1	4
665	Predictive language comprehension in Parkinson's disease. PLoS ONE, 2023, 18, e0262504.	1.1	0
666	Automatic and controlled attentional orienting toward emotional faces in patients with Parkinson's disease. Cognitive, Affective and Behavioral Neuroscience, 2023, 23, 371-382.	1.0	1
667	Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinson's Disease: A Basic and Clinical Approach. Brain Sciences, 2023, 13, 508.	1.1	6
668	Robot-assisted investigation of sensorimotor control in Parkinson's disease. Scientific Reports, 2023, 13, .	1.6	1
669	Sex differences in Parkinson disease-associated episodic memory and processing speed deficits. Journal of the International Neuropsychological Society, 0, , 1-8.	1.2	0
678	Green tea polyphenols for neuroprotection: effects against Alzheimer's and Parkinson's diseases. , 2024, , 1545-1562.		0